EMulate Therapeutics, Inc. (EMTX)

EMulate Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) 255,000
Net Income (ttm) -28.02M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About EMTX

EMulate Therapeutics is on a mission to advance the development and adoption of medical, health, and environmental applications of our low-to-ultra-low radio frequency energy technology that are determined by the FDA (or other applicable regulators) to be non-toxic, non-invasive, non-ionizing, safe and effective. We have invented and patented what we believe to be a groundbreaking technology that utilizes radio frequency energy (RFE) precisely targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®) to specifically regulate signalin... [Read more...]

Industry Health Care
Founded 2002
CEO Chris Rivera
Employees 7
Stock Exchange NASDAQ
Ticker Symbol EMTX
Full Company Profile

Financial Performance

Financial Statements


Medical device developer EMulate Therapeutics files for a $15 million IPO

EMulate Therapeutics, which is developing a non-invasive medical device using radio frequency energy technology, filed on Tuesday with the SEC to raise up to $15 million in an initial public offering.

1 month ago - Renaissance Capital

EMulate Therapeutics IPO Registration Document (S-1)

EMulate Therapeutics has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC